Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

Daudén, E.; Lima, Glauber Pacelli Gomes de; Armesto, Susana; Herrera‐Acosta, Enrique; Vidal, David; Villarasa, Eva; Rivera, R.; Cueva, Pablo de la; Martorell, A.; Ballescá, F.; Belinchón, I.; Carretero, G.; Rodríguez, Lourdes; Romero‐Maté, Alberto; Pujol-Montcusí, Josep; Salgado, L.; Sahuquillo‐Torralba, Antonio; Coto‐Segura, Pablo; Baniandrés, Ofelia; Feltes, Rosa; Alsina, M.; Llamas‐Velasco, Mar

doi:10.1007/s13555-021-00606-9

Cited by 15 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, our results demonstrated that elapsed time since diagnosis to start of treatment with secukinumab ≥5 years was positively associated with a higher probability of secukinumab continuation, being regarded as a predictor for persistence in our analysis. This finding contrasts with data reported in the literature 13 and deserves further investigation. Conversely, patients who had previously experienced other biologic treatments or had been diagnosed with DTL PsO were found to present lower drug persistence rates.…”

Section: Patient Characteristics (N = 302)contrasting

confidence: 99%

Persistence, effectiveness, and real‐world outcomes in psoriasis patients treated with secukinumab in Portugal

Mendes‐Bastos

Morais²,

Ferreira

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

To characterize moderate to severe psoriasis (PsO) adult patients treated with secukinumab, estimate drug persistence and assess any reasons for treatment discontinuation. Non‐interventional, retrospective, longitudinal record‐based study including patients diagnosed with PsO who started secukinumab between January 2018 and January 2020. Baseline characteristics were analyzed by descriptive statistics; drug persistence and predictive factors were assessed through Kaplan–Meier curves and univariate and multivariate analysis, respectively. A total of 302 patients were included in the study: mean age was 48.4 years, 41.7% were female, median time since diagnosis was 12.9 years. 51.3% of patients were bio‐naïve while 48.7% had previously been treated with biologics. PsO in difficult‐to‐treat locations (DTL) was present in 82.1% of patients, with scalp PsO in about half of patients. At 5‐years follow‐up, 84 patients discontinued secukinumab, 45 of which due to loss of efficacy. At week 104, overall treatment persistence was 71.7%. A higher probability of drug persistence was identified among those patients who initiated secukinumab ≥5 years after diagnosis, were bio‐naïve or treated with only one previous biologic, had no PsO on DTL, and had diabetes mellitus. The predictive factors for discontinuation identified in our study were the start of secukinumab <5 years after diagnosis (p = 0.001), the bio‐experimented status with ≥2 biologics (p = 0.007), and the presence of PsO on DTL (p = 0.014). A time since diagnosis of ≥5 years, naïve status or previous use of only one biologic are predictors for secukinumab persistence, whereas the presence of PsO on DTL predicts drug discontinuation.

show abstract

Section: Patient Characteristics (N = 302)contrasting

confidence: 99%

Persistence, effectiveness, and real‐world outcomes in psoriasis patients treated with secukinumab in Portugal

Mendes‐Bastos

Morais²,

Ferreira

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…7,8 Consequently, real-world studies have shown conflicting results for the drug survival of secukinumab in patients with psoriasis. [12][13][14] In a real-world setting involving Spanish patients, secukinumab showed consistent effectiveness and drug survival results, independent of patient status of biologic-naïve or biologicexperienced. 2 A clinical study conducted over a 5-year period demonstrated high and sustainable levels of skin clearance following treatment with secukinumab, along with a favourable safety profile in patients with moderate to severe CPP.…”

Section: Introductionmentioning

confidence: 84%

“…The Dutch BioCAPTURE registry provides another example of drug survival of secukinumab. The study reported biologic‐naïve patients as having a 1‐year survival function of 0.90, compared with 0.74 survival function for biologic‐experienced patients 14,19 …”

Section: Discussionmentioning

confidence: 99%

“…The study reported biologic-naïve patients as having a 1-year survival function of 0.90, compared with 0.74 survival function for biologic-experienced patients. 14,19 As SUSTAIN was based on the secondary use of data, the safety analyses were provided on an aggregate level.…”

Section: Discussionmentioning

confidence: 99%

“…Results of drug survival rate studies of biologics for psoriasis differ with study design and population 7,8 . Consequently, real‐world studies have shown conflicting results for the drug survival of secukinumab in patients with psoriasis 12–14 . In a real‐world setting involving Spanish patients, secukinumab showed consistent effectiveness and drug survival results, independent of patient status of biologic‐naïve or biologic‐experienced 2 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study)

et al. 2022

View full text Add to dashboard Cite

Background Drug survival measures the rate and duration of adherence to a given therapeutic agent and evaluates its long‐term effectiveness, safety, and real‐world utility. The SUSTAIN study sought to establish the drug survival and effectiveness of secukinumab for patients with severe chronic plaque psoriasis (CPP) in the Australian clinical setting. Methods Data of all patients (aged ≥18 years) from Australasian Psoriasis Registry (APR) treated with secukinumab were analysed. The primary objective was to describe the drug survival of secukinumab at 9 months. Key secondary objectives included drug survival of secukinumab at 3, 6, 15, and 21 months, stratified by biologic‐naïve vs biologic‐experienced patients; proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75/90/100 responses; and changes in health‐related quality of life over time utilising the Dermatology Life Quality Index (DLQI). Results Of 294 patients included in this analysis, 110 (37.4%) were biologic‐naïve and 184 (62.6%) biologic‐experienced. Kaplan–Meїer drug survival rates in biologic‐naïve vs biologic‐experienced patients were 0.92 vs. 0.86 (9 months) and 0.82 vs. 0.68 (21 months), respectively. The proportion of patients with PASI 75/90/100 responses for biologic‐naïve vs. biologic‐experienced was 100/87.7/38.4 vs 98.5/61.5/27.2 (9 months) and 100/81.0/41.7 vs. 98.4/62.0/24.2 (21 months), respectively. The mean (standard deviation [SD]) DLQI in biologic‐naïve vs. experienced patients was 2.2 (4.1) vs. 3.1 (5.2) (9 months) and 1.4 (2.5) vs. 3.1 (5.3) (21 months). No new safety signals were observed. Conclusions Secukinumab demonstrated high drug survival and sustained effectiveness in Australian real‐world setting, in biologic‐naïve and biologic‐experienced patients with severe CPP.

show abstract

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Ramos

Puchades

Climent

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

BackgroundThere is limited evidence over the real‐life secukinumab survival in psoriatic patients, especially in the long‐term bio‐naïve subjects, and to date biological treatments have been assessed in patients with a chronic and recalcitrant psoriasis. It has been hypothesised that early intensive treatment with biological therapies could decrease pathogenic tissue resident memory (TRm) cells migration and potentially modify the natural course of psoriasis and related comorbidities.ObjectivesTo analyze long‐term secukinumab efficacy, safety and survival, and its predictive factors for psoriasis treatment determining also whether early intervention may result in better outcomes for patients.MethodsBio‐naïve psoriatic patients under treatment with secukinumab (n = 128 patients) in a daily practice setting were analyzed in a retrospective multicentric study and followed up to 8 years. Drug survival rate, efficacy, posology and safety were reported.ResultsThe overall secukinumab survival was 81.9% for an average treatment exposure of 147.9 weeks. The approved posology was the most commonly prescribed regimen (78.7%), and 17.7% could be optimized. An absolut‐PASI ≤3 was reached by 86.6%, 82.6% and 91.7% at the weeks 48,156 and 264, respectively. The incidence of arthritis or psoriasis related comorbidities was low. The response was not influenced by weight, age (>65), gender or the presence of arthritis. No severe adverse events were reported.ConclusionsIn our bio‐naïve series, the high efficacy and long‐term survival rates observed and the low prevalence of arthritis and comorbidities might suggest that early intervention could contribute to modify the course of the disease, but further studies are needed.

show abstract

Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

Cited by 15 publications

References 21 publications

Persistence, effectiveness, and real‐world outcomes in psoriasis patients treated with secukinumab in Portugal

Persistence, effectiveness, and real‐world outcomes in psoriasis patients treated with secukinumab in Portugal

Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study)

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

Contact Info

Product

Resources

About